Scilex Holding Co (SCLX)

NASDAQ
Currency in USD
0.344
-0.010(-2.80%)
Real-time Data
SCLX Scorecard
Full Analysis
Valuation implies a strong free cash flow yield
Fair Value
Day's Range
0.3380.358
52 wk Range
0.3302.630
Key Statistics
Edit
Prev. Close
0.354
Open
0.347
Day's Range
0.338-0.358
52 wk Range
0.33-2.63
Volume
664.15K
Average Vol. (3m)
1.48M
1-Year Change
-81.07%
Book Value / Share
-1.6
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCLX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
10.650
Upside
+2,995.93%
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets
Show more

Scilex Holding Co Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.

Employees
117

Compare SCLX to Peers and Sector

Metrics to compare
SCLX
Peers
Sector
Relationship
P/E Ratio
−0.7x−0.5x−0.7x
PEG Ratio
−0.020.000.00
Price / Book
−0.3x0.9x2.6x
Price / LTM Sales
1.1x1.4x3.1x
Upside (Analyst Target)
-190.7%49.4%
Fair Value Upside
Unlock14.9%8.9%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.650
(+2,995.93% Upside)

Earnings

Latest Release
May 12, 2023
EPS / Forecast
-0.22 / --
Revenue / Forecast
10.58M / --
EPS Revisions
Last 90 days

People Also Watch

1.350
PYXS
0.00%
2.2980
NIVF
+4.93%
2.5599
TCBP
+0.39%
3.990
ALUR
-28.50%
0.831
CNTX
+0.17%

FAQ

What Is the Scilex Holding (SCLX) Stock Price Today?

The Scilex Holding stock price today is 0.344

What Stock Exchange Does Scilex Holding Trade On?

Scilex Holding is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Scilex Holding?

The stock symbol for Scilex Holding is "SCLX."

What Is the Scilex Holding Market Cap?

As of today, Scilex Holding market cap is 62.67M.

What is Scilex Holding Earnings Per Share?

The Scilex Holding EPS is -0.775.

From a Technical Analysis Perspective, Is SCLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.